Drug intelligence / Profile preview

chakasaponin I

Development stage: Preclinical
Lead developer: Alderson Broaddus University
Modality: Small Molecules
Administration: Parenteral

Overview

Chakasaponin I is an oleanane-type triterpene saponin isolated from the flowers of the tea plant (*Camellia sinensis*). It has demonstrated anti-proliferative and pro-apoptotic activities in preclinical models, specifically against cisplatin-resistant ovarian cancer cells such as OVCAR-3. The compound induces apoptosis via the intrinsic pathway, characterized by the dose-dependent activation of pro-apoptotic proteins Bad and Bax. As a major constituent of tea flower saponins (TFS), it is being investigated for its potential as a natural anticancer agent.

Targets

BAX (Apoptosis regulator BAX)BAD (Bcl-2-associated agonist of cell death)

Beyond the preview

Go deeper on chakasaponin I.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on chakasaponin I.

Explore the full profile